COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,358 Articles (22,803 medRxiv, 8,555 bioRxiv)

Most recent first Previous |  Page 1412: Articles 14111-14120  | Next

Mutation signatures inform the natural host of SARS-CoV-2
He, X.
10.1101/2021.07.05.451089 — Posted: 2021-07-05
Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection
Li, L., Honda-Okubo, Y., Huang, Y., Jang, H., Carlock, M. A., Baldwin, J., Piplani, S., Bebin-Blackwell, A. G., Forgacs, D., Sakamoto, K., Stella, A., Turville, S., Chataway, T., Colella, A., Triccas, J., Ross, T., Petrovsky, N.
10.1101/2021.07.03.451026 — Posted: 2021-07-05
Predicted Impact of the Viral Mutational Landscape on the Cytotoxic Response against SARS-CoV-2
Foix, A., Lopez, D., McConnell, M. J., Martin-Galiano, A. J.
10.1101/2021.07.04.451040 — Posted: 2021-07-05
Dynamics of SARS-CoV-2 host cell interactions inferred from transcriptome analyses
Adam, L., Stanifer, M., Springer, F., Mathony, J., Di Ponzio, C., Eils, R., Boulant, S., Niopek, D., Kallenberger, S. M.
10.1101/2021.07.04.450986 — Posted: 2021-07-05
A SARS-CoV-2 nucleocapsid protein TR-FRET assay amenable to high-throughput screening
Gorshkov, K., Vasquez, D. M., Chiem, K., Ye, C., Nguyen Tran, B., de la Torre, J. C., Moran, T., Chen, C. Z., Martinez-Sobrido, L., Zheng, W.
10.1101/2021.07.03.450938 — Posted: 2021-07-05
A cGAMP-containing hydrogel for prolonged SARS-CoV-2 RBD subunit vaccine exposure induces a broad and potent humoral response
Gale, E. C., Lahey, L. J., Böhnert, V., Powell, A. E., Ou, B. S., Carozza, J. A., Li, L., Appel, E.
10.1101/2021.07.03.451025 — Posted: 2021-07-05
SARS-CoV-2 environmental contamination from hospitalised COVID-19 patients receiving aerosol generating procedures
Winslow, R., Zhou, J., Windle, E. F., Nur, I. X., Lall, R., Millar, J. E., Dark, P. M., Naisbitt, J., Simonds, A., Dunning, J., Barclay, W., Baillie, J. K., Perkins, G. D., Semple, M. G., McAuley, D. F., Green, C. A.
10.1101/2021.07.04.21259945 — Posted: 2021-07-05
Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection
Harrington, W. E., Jiang, Y., Duffy, F., Hadlock, J., Raappana, A., Styrchak, S., Beck, I., Chour, W., Houck, J., Duvvuri, V., Yeung, W., Haglund, M., Wallner, J., Wallick, J., Hardy, S., Oldroyd, A., Ko, D., Gervassi, A., Murray, K., Kaplan, H., Aitchison, J., Heath, J., Sather, D. N., Goldman, J., Frenkel, L.
10.1101/2021.06.30.21259796 — Posted: 2021-07-05
Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory
Mateus, J., Dan, J. M., Zhang, Z., Rydyznski Moderbacher, C., Lammers, M., Goodwin, B., Sette, A., Crotty, S., Weiskopf, D.
10.1101/2021.06.30.21259787 — Posted: 2021-07-05 Discussion: Onsite
Reduced COVID-19 Hospitalizations among New York City Residents Following Age-Based SARS-CoV-2 Vaccine Eligibility: Evidence from a Regression Discontinuity Design
Greene, S. K., Levin-Rector, A., McGibbon, E., Baumgartner, J., Devinney, K., Ternier, A., Sell, J., Kahn, R., Kishore, N.
10.1101/2021.06.30.21259491 — Posted: 2021-07-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).